Takis Biotech Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
46
- Latest Deal Type
-
Later Stage VC
- Investors
-
1
Takis Biotech General Information
Description
Operator of a biotechnology company intended to harness the immune system to fight cancer and infectious diseases. The company offers validation of new targets for the treatment of chronic viral diseases and cancer, and also provides technologies to improve in vivo gene transfer, regulation of gene expression, and immunogenicity, enabling doctors to identify novel targets for cancer immunotherapy.
Contact Information
Website
www.takisbiotech.comCorporate Office
- Via Castel Romano 100
- 00128 Rome
- Italy
Corporate Office
- Via Castel Romano 100
- 00128 Rome
- Italy
Takis Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC | Completed | Generating Revenue |
Takis Biotech Comparisons
Industry
Financing
Details
Takis Biotech Competitors (4)
One of Takis Biotech’s 4 competitors is Arbutus Biopharma, a Corporation company based in Warminster, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arbutus Biopharma | Corporation | Warminster, PA | ||||
| Sibylla Biotech | Venture Capital-Backed | Verona, Italy | ||||
| ENYO Pharma | Venture Capital-Backed | Lyon, France | ||||
| GeoVax Labs | Corporation | Smyrna, GA |
Takis Biotech Patents
Takis Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026088233-A1 | Humanised sequence for the generation of anti-erbb3/her3 antibodies | Pending | 24-Oct-2024 | ||
| EP-4401778-A1 | Antibodies against sars-cov-2 and uses thereof in the medical field | Pending | 16-Sep-2021 | ||
| US-20240382586-A1 | Antibodies against sars-cov-2 and uses thereof in the medical field | Pending | 16-Sep-2021 | ||
| WO-2023042235-A1 | Antibodies against sars-cov-2 and uses thereof in the medical field | Inactive | 16-Sep-2021 | ||
| EP-4142783-A1 | Polynucleotides encoding sars-cov-2 antigens and use thereof in the medical field as vaccines | Pending | 30-Apr-2020 | A61K39/12 |
Takis Biotech Signals
Takis Biotech Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Lazio Innova | Venture Capital | Minority |
Takis Biotech Investments (1)
Takis Biotech’s most recent deal was a Spin-Off with Neomatrix. The deal was made on 01-Jan-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Neomatrix | 01-Jan-2020 | Spin-Off | Drug Discovery |
Takis Biotech FAQs
-
When was Takis Biotech founded?
Takis Biotech was founded in 2009.
-
Where is Takis Biotech headquartered?
Takis Biotech is headquartered in Rome, Italy.
-
What is the size of Takis Biotech?
Takis Biotech has 46 total employees.
-
What industry is Takis Biotech in?
Takis Biotech’s primary industry is Biotechnology.
-
Is Takis Biotech a private or public company?
Takis Biotech is a Private company.
-
What is Takis Biotech’s current revenue?
The current revenue for Takis Biotech is .
-
Who are Takis Biotech’s investors?
Lazio Innova has invested in Takis Biotech.
-
Who are Takis Biotech’s competitors?
Arbutus Biopharma, Sibylla Biotech, ENYO Pharma, and GeoVax Labs are competitors of Takis Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process